Interventional randomized double-blind parallel-group placebo-controlled multi-centre study to assess the efficacy safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy

Brief description of study

The purpose of this study is to find out whether a potential new treatment, the investigational drug Lu AF82422, is safe and effective in people living with MSA. This study will compare the effects of the investigational drug Lu AF82422 to placebo (inactive medication). An investigational drug is one that has not been approved by the FDA, the health authority that gives approval for new medicines to be prescribed in the United States. A placebo looks like the investigational drug but does not contain any active medicine. Researchers use a placebo to see if a research medicine works better or is safer than not taking anything at all.

Clinical Study Identifier: s21-00956

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.